Airdoc Secures B+ Financing Led by CITIC Consortium and Ping An Global Voyager Fund, Advances Toward IPO

In 2018, Airdoc, an AI company in the healthcare sector, completed a new round of B+ financing within the year, following its Series B funding led by Fosun and with follow-on investment from its Series A investor, Sogou. This round was jointly invested by the CITIC Consortium and Ping An Global Voyager Fund.

CITIC’s investment in Airdoc not only demonstrates its strategic layout in the field of medical artificial intelligence, aiming to accelerate the realization of the “Healthy China 2030” goals by increasing investments in high-tech sectors, but also serves as an endorsement of Airdoc’s leading technology and reliable services.

Jonathan Larsen, Chief Innovation Executive of Ping An Group and CEO of Ping An Global Voyager Fund, stated: “This is an important investment for the Ping An Global Voyager Fund. Airdoc brings world-class AI-driven, image-based diagnostic capabilities across multiple domains. There are many applications for their solutions within the Ping An health and financial services ecosystem, in China, regionally, and internationally. We are excited to be working with such a high-quality team both as an investor and a strategic partner.”

(“This is a significant investment for Ping An Global Navigator Fund. Airdoc provides world-class, AI-driven, image-based analytical capabilities across multiple domains. There are numerous applications for its solutions within the Ping An Health and Financial Services ecosystem, both regionally and internationally. As an investor and strategic partner, we are delighted to collaborate with such a high-caliber team.”)

Dr. Marco Huesch, Chief Medical Officer of Ping An Global Voyager Fund, stated, “Airdoc’s market-leading medical AI retinal imaging technology offers consumers a fast, convenient, and accurate screening service for major diseases, available at multiple retail check-up center locations across China. We anticipate further local, regional, and international expansion of this innovative service as patients, primary care providers, specialists, and insurers increasingly recognize the benefits of sophisticated, cost-effective screening for significant ocular and systemic diseases.”

(“Airdoc’s market-leading AI-based retinal imaging technology provides consumers with rapid, convenient, and accurate screening services for major diseases, which are available at numerous health examination centers across China. We anticipate that this innovative service will expand further both domestically and internationally, as patients, primary healthcare institutions, specialists, and insurance companies increasingly recognize the benefits of mature and efficient screening for significant ophthalmic and systemic diseases.”)

The application of AI technology for early disease detection in large populations is of great significance. Airdoc works daily with numerous partners to help society identify individuals with health issues, enabling low-cost early detection and timely intervention of diseases, which is crucial for individuals, families, and society as a whole.

Upon the completion of this round of financing, Airdoc will continue to work diligently with its strategic shareholders and partners to promote the application of AI health technologies, ensuring that high-quality health services benefit everyone.